RMS

1,636

+1.24%↑

BMW

77.18

+4.27%↑

VOW

87.65

+2.75%↑

VOW3

85.74

+2.46%↑

KER

247.25

+5.28%↑

RMS

1,636

+1.24%↑

BMW

77.18

+4.27%↑

VOW

87.65

+2.75%↑

VOW3

85.74

+2.46%↑

KER

247.25

+5.28%↑

RMS

1,636

+1.24%↑

BMW

77.18

+4.27%↑

VOW

87.65

+2.75%↑

VOW3

85.74

+2.46%↑

KER

247.25

+5.28%↑

RMS

1,636

+1.24%↑

BMW

77.18

+4.27%↑

VOW

87.65

+2.75%↑

VOW3

85.74

+2.46%↑

KER

247.25

+5.28%↑

RMS

1,636

+1.24%↑

BMW

77.18

+4.27%↑

VOW

87.65

+2.75%↑

VOW3

85.74

+2.46%↑

KER

247.25

+5.28%↑

Search

D'ieteren SA-NV

Atvērts

SektorsCikliskās patēriņa

161.7 5.14

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

154

Max

163.8

Galvenie mērījumi

By Trading Economics

Ienākumi

-68M

176M

Pārdošana

-71M

4B

P/E

Sektora vidējais

21.954

33.36

Dividenžu ienesīgums

1.16

Peļņas marža

4.413

Darbinieki

12,366

EBITDA

-21M

304M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+34.21% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.16%

3.17%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-234M

9.2B

Iepriekšējā atvēršanas cena

156.56

Iepriekšējā slēgšanas cena

161.7

Ziņu noskaņojums

By Acuity

50%

50%

140 / 338 Rangs Consumer cyclical

D'ieteren SA-NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

D'ieteren SA-NV Prognoze

Cenas mērķis

By TipRanks

34.21% augšup

Prognoze 12 mēnešiem

Vidējais 215 EUR  34.21%

Augstākais 215 EUR

Zemākais 215 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi D'ieteren SA-NV — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

140 / 338 Rangs Cikliskās patēriņa

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par D'ieteren SA-NV

D'Ieteren Group SA operates as an investment company in Belgium, France, rest of Europe, the Middle East, Africa, America, the Asia-Pacific, and internationally. The company operates through D'Ieteren Automotive, Belron, Moleskine, TVH, and PHE segments. It distributes Volkswagen, Audi, SEAT, "KODA, CUPRA, Bentley, Lamborghini, Bugatti, Rimac, Porsche, and Microlino brand vehicles, as well as related spare parts and accessories; sells used vehicles; and offers maintenance, financing, and leasing services. The company also provides vehicle glass repair, replacement, and recalibration services under the Autoglass, Carglass, Lebeau Vitres d'autos, Speedy Glass, Safelite AutoGlass, O'Brien, and Smith&Smith brand names; and manages vehicle glass and other insurance claims on behalf of insurance customers. In addition, it offers notebooks, writing tools, planners, diaries, bags, and reading accessories, as well as smart writing system and mobile apps. Further, the company distributes aftermarket parts for material handling, construction, agricultural, and industrial equipment. Additionally, it manages real estate assets, including offices, workshops, concessions, logistics centers, residential units, car parks, and landbanks; reconverts and redevelops sites; and offers real estate advisory services. D'Ieteren Group SA was founded in 1805 and is headquartered in Brussels, Belgium.
help-icon Live chat